Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Breast Neoplasms 80Neoplasms 72Melanoma 63Neoplasm Metastasis 62Leukemia, Myeloid, Acute 58Ovarian Neoplasms 54Lymphoma, Non-Hodgkin 53Multiple Myeloma 51Prostatic Neoplasms 50Colorectal Neoplasms 50Glioblastoma 48Pancreatic Neoplasms 47Lung Neoplasms 45Recurrence 42Carcinoma, Renal Cell 40Squamous Cell Carcinoma of Head and Neck 37Leukemia, Lymphocytic, Chronic, B-Cell 37Triple Negative Breast Neoplasms 35Myelodysplastic Syndromes 30Lymphoma, Large B-Cell, Diffuse 28Glioma 28Stomach Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell 27Brain Neoplasms 27Lymphoma, Follicular 26Endometrial Neoplasms 26Lymphoma 25Carcinoma, Hepatocellular 24

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × EGFR-mutant Non-small Cell Lung Cancer × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡